ARWRArrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins. Arrowhead Pharmaceuticals focuses on therapeutic areas including cardiometabolic, liver, pulmonary, neuromuscular, complement-mediated, and central nervous system disorders. Its portfolio includes both commercial and clinical-stage programs built around its targeted RNAi platform, which is designed for tissue-specific delivery and precise gene suppression. The company works across product development, clinical research, and commercialization, with a pipeline that includes multiple investigational therapies aimed at genetically driven diseases. Arrowhead Pharmaceuticals serves the broader healthcare market by advancing treatments for complex conditions with limited options, positioning itself as a specialized player in RNA-based drug development.